{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.378","upperLimit":"0.588","value":"0.483"},{"groupId":"OG001","lowerLimit":"0.412","upperLimit":"0.622","value":"0.517"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"The number of pills taken out of the total prescribed in a 3-month period, averaged across all study time points. The proportion of participants with average adherence rate \\>90% is computed by arm and corresponding 95% confidence intervals are reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received Carvedilol PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG000","title":"Arm I (Carvedilol)"},{"description":"Patients received Placebo PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG001","title":"Arm II (Placebo)"}],"paramType":"NUMBER","populationDescription":"We excluded 31 participants who did not have a second time point assessment of echocardiography, resulting in 151 analyzable participants.","reportingStatus":"POSTED","timeFrame":"Average adherence across 6 months, 12 months, 18 months, 24 months after treatment initiation are calculated.","title":"Proportion of Participants With Average Adherence > 90%","type":"SECONDARY","unitOfMeasure":"proportion of participants"}